| Laura Alsteen, APNP | |
|
1621 N Taylor Dr, Suite 300, Sheboygan, WI 53081-1990 | |
| (920) 496-4700 | |
| Not Available |
| Full Name | Laura Alsteen |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 14 Years |
| Location | 1621 N Taylor Dr, Sheboygan, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114215886 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 444533-20 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Nicholas Hospital | Sheboygan, WI | Hospital |
| St Vincent Hospital | Green bay, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St. Nicholas Hospital-sisters Of The Third Order Of St Francis | 8325931652 | 150 |
News Archive
Based on a review of the latest evidence, the Guidelines Committee of the Heart Failure Society of America now recommends that the use of cardiac resynchronization therapy (CRT) be expanded to a larger group of patients with mild heart failure symptoms.
A quiet transformation has been brewing in medicine, as large-scale DNA results become increasingly available to patients and healthcare providers.
Politico: "White House senior adviser David Axelrod says President Barack Obama would like to have a public option – or government-run insurance plan – as part of a health reform package, but will not insist on it.
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that patients are being enrolled in a Phase 1 clinical trial evaluating IPI-493 in patients with advanced hematologic malignancies. This multi-center study is the second clinical trial of IPI-493, Infinity's oral heat shock protein 90 (Hsp90) chaperone inhibitor.
› Verified 8 days ago
| Entity Name | St. Nicholas Hospital-sisters Of The Third Order Of St Francis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275799413 PECOS PAC ID: 8325931652 Enrollment ID: O20040202001172 |
News Archive
Based on a review of the latest evidence, the Guidelines Committee of the Heart Failure Society of America now recommends that the use of cardiac resynchronization therapy (CRT) be expanded to a larger group of patients with mild heart failure symptoms.
A quiet transformation has been brewing in medicine, as large-scale DNA results become increasingly available to patients and healthcare providers.
Politico: "White House senior adviser David Axelrod says President Barack Obama would like to have a public option – or government-run insurance plan – as part of a health reform package, but will not insist on it.
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that patients are being enrolled in a Phase 1 clinical trial evaluating IPI-493 in patients with advanced hematologic malignancies. This multi-center study is the second clinical trial of IPI-493, Infinity's oral heat shock protein 90 (Hsp90) chaperone inhibitor.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura Alsteen, APNP 1621 N Taylor Dr, Suite 300, Sheboygan, WI 53081-1990 Ph: (920) 496-4700 | Laura Alsteen, APNP 1621 N Taylor Dr, Suite 300, Sheboygan, WI 53081-1990 Ph: (920) 496-4700 |
News Archive
Based on a review of the latest evidence, the Guidelines Committee of the Heart Failure Society of America now recommends that the use of cardiac resynchronization therapy (CRT) be expanded to a larger group of patients with mild heart failure symptoms.
A quiet transformation has been brewing in medicine, as large-scale DNA results become increasingly available to patients and healthcare providers.
Politico: "White House senior adviser David Axelrod says President Barack Obama would like to have a public option – or government-run insurance plan – as part of a health reform package, but will not insist on it.
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that patients are being enrolled in a Phase 1 clinical trial evaluating IPI-493 in patients with advanced hematologic malignancies. This multi-center study is the second clinical trial of IPI-493, Infinity's oral heat shock protein 90 (Hsp90) chaperone inhibitor.
› Verified 8 days ago
Erin Jessie Holzman, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2414 Kohler Memorial Dr, Sheboygan, WI 53081 Phone: 920-457-4461 | |
Mrs. Doris U Theune, MS RN CS Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2920 Superior Ave, Sheboygan, WI 53081 Phone: 920-453-5414 Fax: 920-803-2990 | |
Dr. Amanda Beinemann, AGPCNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3100 Superior Ave, Sheboygan, WI 53081 Phone: 920-459-8300 | |
Mary Lou Roethel, MSN,NP-C,APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1621 N Taylor Dr, Suite 300, Sheboygan, WI 53081 Phone: 920-496-4700 | |
Jennifer L Thickens, APNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3100 Superior Ave, Sheboygan, WI 53081 Phone: 920-496-4700 | |
Connie Lee Worm, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2108 Kohler Memorial Dr, Sheboygan, WI 53081 Phone: 920-458-9401 Fax: 920-458-8801 | |
Christopher Klika, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1411 N Taylor Dr, Sheboygan, WI 53081 Phone: 920-457-4858 |